February 2010 Volume 6, Issue 2
Volume 6, Issue 2 | February 2010
February 2010
In this Issue
Global News
Not seeing eye-to-eye
Novartis seeks to acquire eye giant Alcon, but is meeting resistancePardon the disruption
Roche and Evolva use discovery platform to create compounds that mimic those that are naturally occurringTaking aim at cancer
Merck strikes deal with Cancer Research UK for investigational anti-cancer drug targeting leukemia and lymphomaTeva expands pipeline
Company inks license agreement to commercialize OncoGenex’s late-stage treatment for cancerResearch & Development
Pfizer ‘invests to win’
Following Wyeth merger, multiple recent deals and job layoffs, pharma refocuses drug development pipelineThe path of least resistance
AstraZeneca acquires Novexel, expands collaboration with Forest Laboratories in effort to boost antibiotic pipelineInflammation collaboration
Eli Lilly and Incyte strike worldwide license and collaboration deal for the development and commercialization of Incyte's oral JAK1/JAK2 inhibitor for inflammatory and autoimmune diseasesAmbit and Astellas Pharma: Working to release your inhibitors
They aim to develop FLT3 kinase inhibitors for AML and moreFragile hope for brain disorders
Seaside Therapeutics, Vanderbilt collaborate on novel therapeutics to treat Fragile X, autism, other brain disordersContract Services
Chorus hits high notes for Lilly
Special R&D unit takes control of compounds discovered in other companies’ labsPPD completes acquisition of BioDuro
Pharmaceutical Product Development Inc. finalizes acquisition of BioDuro, a drug discovery outsourcing company focused on integrated drug discovery programs and servicesContract research market eyes growth
Market research reports find many pressures facing pharma, biotech companies lead them to outsource research servicesGood planning, good results
Quintiq provides advanced planning and scheduling platform to global CRO PRA InternationalDiagnostics
Let's make a deal
Bio-Rad Laboratories completes purchase of certain diagnostics businesses of Biotest AG for $67.5 millionCancer leaves its (bio)mark
Strategic Diagnostics and Fred Hutchinson Cancer seek biomarkers for use in early detection of a variety of cancersDefining cancer by pathways
Clarient’s acquisition of Applied Genomics targets NSCLC diagnosticsLast-minute holiday shopping bags OncoDiagnotics for Predictive Biosciences
Predictive Biosciences did a little last-minute holiday shopping in December, closing a deal to acquire Cleveland-based OncoDiagnostic LaboratoryInstruments & Informatics
Sorting it all out
OncoMed Pharmaceuticals and Fluidigm Corp. announce strategic collaboration aimed at sorting and analyzing tumor cells, especially cancer stem cellsHawkeyeish on technology
DNASTAR and the University of Iowa sign Lasergene site license agreementIn it together
Thermo and Cerilliant offer certified solution standards for forensic and clinical research laboratoriesPartnering on pathways
GeneGo links informatics software to Sigma-Aldrich productsOmics & Systems Biology
Getting the fat in
MIT and Alnylam researchers find way to turn off multiple genes at once with RNAi therapyStreamlined sequencing for sale
Agilent Technologies and Covaris sign co-marketing agreement pairing target enrichment with DNA shearing for next-gen sequencingPower times two
Silence Therapeutics merges with Intradigm Corp. to create RNAi therapeutics companyBringing in the proteome
ALS research organization teams up with Applied Proteomics to work on biomarker developmentEditor's Focus
Cleveland: The next biotech hub?
Couls we attract biotech and pharma companies to Cleveland, where the median home price is about $106,000, and opportunities to work with some of the country’s most highly regarded hospital and educational institutions — the Cleveland Clinic and Case Western Reserve University (CWRU), to name two — abound?Patent News
Why are drugs expensive in the U.S.? Because other countries decide to pay less
Pfizer is continuing its fight with generic drug manufacturer United Laboratories =in the Philippines over the issue of the validity of the patent on Lipitor as Unilab tries to have the patent canceled.Commentary
Guest Commentary: Academic institutions play active role in early-stage drug discovery process
In the past decade, the role academic intuitions play in drug discovery has evolved, with more emphasis being placed on finding the chemical compounds that can modulate that promising target.News Briefs
Show Preview: 49th Annual Meeting and ToxExpo of the Society of Toxicology
Annual SOT meeting to be held March 7 to 11 at Salt Lake City’s Salt Palace Convention Center
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Discovering deeper insights into malaria research
Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Accelerating RNA therapeutic testing with liver microphysiological platforms
Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
Shining light on the subcellular proteome
Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
